MDGL Madrigal Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MDGL

Price (delayed)

$284.88

Market cap

$5.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$18.1

Enterprise value

$5.18B

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum ...

Highlights
The company's quick ratio rose by 17% YoY and by 8% QoQ
The equity is down by 24% since the previous quarter but it is up by 3% year-on-year
The debt has surged by 70% since the previous quarter
The company's net income fell by 28% YoY and by 7% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.madrigalpharma.com
Peers: OCUP

Key stats

What are the main financial stats of MDGL
Market
Shares outstanding
18.29M
Market cap
$5.21B
Enterprise value
$5.18B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
34.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$308.43M
EBITDA
-$307.94M
Free cash flow
-$259.21M
Per share
EPS
-$18.1
Free cash flow per share
-$14.25
Book value per share
$8.28
Revenue per share
$0
TBVPS
$18.28
Balance sheet
Total assets
$332.45M
Total liabilities
$182.31M
Debt
$84.62M
Equity
$150.14M
Working capital
$232.94M
Liquidity
Debt to equity
0.56
Current ratio
3.37
Quick ratio
3.35
Net debt/EBITDA
0.09
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-117.6%
Return on equity
-285%
Return on invested capital
-353%
Return on capital employed
-131.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MDGL stock price

How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
1.17%
1 week
2.99%
1 month
-7.29%
1 year
316.43%
YTD
-1.85%
QTD
17.59%

Financial performance

How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$314.32M
Net income
-$314.73M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 28% YoY and by 7% QoQ
MDGL's operating income is down by 27% YoY and by 7% QoQ

Growth

What is Madrigal Pharmaceuticals's growth rate over time

Valuation

What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
34.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 23% YoY and by 5% from the previous quarter
The stock's price to book (P/B) is 161% more than its 5-year quarterly average of 13.2 but 21% less than its last 4 quarters average of 43.3
The equity is down by 24% since the previous quarter but it is up by 3% year-on-year

Efficiency

How efficient is Madrigal Pharmaceuticals business performance
Madrigal Pharmaceuticals's ROIC has plunged by 147% YoY but it has increased by 25% from the previous quarter
The ROE has plunged by 145% YoY and by 6% from the previous quarter
MDGL's return on assets is down by 34% year-on-year but it is up by 4.4% since the previous quarter

Dividends

What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDGL.

Financial health

How did Madrigal Pharmaceuticals financials performed over time
Madrigal Pharmaceuticals's total assets is 82% more than its total liabilities
Madrigal Pharmaceuticals's total liabilities has soared by 137% YoY and by 10% from the previous quarter
Madrigal Pharmaceuticals's total assets has increased by 49% YoY but it has decreased by 8% from the previous quarter
The debt is 44% smaller than the equity
Madrigal Pharmaceuticals's debt to equity has surged by 124% QoQ
The debt has surged by 70% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.